This may explain, in part, why nuclear PTHrP is associated with the unfavorable clinical outcomes since loss of Stat5 expression and activation in breast cancer has consistently been associated with poor prognosis (144, 145). This evidence concerns the gene PTHLH and breast carcinoma.